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Aging is the single most important risk factor in human 
disease in developed countries but when it comes to 
research on prevention or cures, aging is seldom taken 
into account. Nevertheless if aging is a significant 
contributor to age-related conditions, we would hope 
that an understanding of aging mechanisms could 
prompt the design of rational therapies. Moreover, if 
aging causes multiple diseases then it is reasonable to 
think that pharmacological agents that slow aging could 
be also effective in preventing or slowing a wide 
spectrum of diseases. 
 
Considerable progress has been made in understanding 
the genetic influences on lifespan in simple metazoans. 
In particular, the longevity of the nematode 
Caenorhabditis elegans ( C. elegans) is influenced by 
hundreds of genes and metabolic processes including an 
insulin signaling-like (ISL) pathway that regulates the 
FOXO-like transcription factor DAF-16 [1]. The ISL 
influences many processes including development, 
fertility and stress resistance. Its influence on the ability 
to withstand stress presents a connection to disease that 
could be exploited pharmacologically. In concert with 
the stress response transcription factor, Heat Shock 
Factor 1 (HSF-1), DAF-16 regulates the formation of 
toxic protein aggregation, reduces the sensitivity to 
stress and increases lifespan in C. elegans [2, 3]. This 
points to a critical role for protein aggregation in aging. 
 
Protein aggregation is a hallmark of aging and several 
age-related pathologies, collectively known as 
conformational diseases (CD) [4]. This similarity 
strongly suggests a crosstalk between aging and disease. 
Although it is not clear how protein aggregation occurs, 
dramatic alterations in the balance of protein synthesis, 
protein folding and protein degradation (together  repre- 
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senting “protein homeostasis”) are likely to play 
important roles in this process. As a consequence, 
modified proteins tend to accumulate into soluble 
oligomers and insoluble aggregates that may actively 
influence cell function. Neurodegenerative diseases are 
arguably the best studied CD and the aberrant 
aggregation of several insoluble molecules like α-
synuclein (Parkinson’s), β-amyloid (Alzheimer’s) and 
huntingtin (Huntington’s) has long been associated with 
the development of these pathologies [5]. However, 
other non-neurological, systemic diseases like type II 
diabetes and several myopathies, are also 
conformational diseases.  
 
The general picture that that has emerged is that 
conformationally-altered proteins escape the 
surveillance of repair and degradation systems, form 
aggregates, and this process contributes to aging; aging 
could be therefore a manifestation of a loss in protein 
homeostasis. This then prompts the question: to what 
extent could chemical modulation of protein 
aggregation alter the rate of aging? Furthermore, would 
such an intervention influence disease pathology? 
 
In a recent publication, we addressed this issue by 
identifying small molecules able to slow protein 
aggregation in the C. elegans model. We were then able 
to directly assess the degree to which protein 
aggregation influences normal aging rates [6]. We 
undertook a focused screen of chemical compounds that 
exhibit protein aggregate-binding properties, such as 
Thioflavin T (ThT) and curcumin, widely used to stain 
these aggregates in post-mortem tissues of neurological 
disease affected individuals. We found that exposing 
wildtype worms to 50 µM ThT throughout the adult life 
leads to an increase in median and maximal lifespan and 
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compound also slowed age-related decline in 
spontaneous movement throughout adulthood which 
generally indicates improved health. However, at higher 
concentrations (500 µM), ThT was clearly toxic. 
Whether this is the result of “off target” side effects or 
something specific to protein aggregation is not clear.  
Interestingly, we found that several compounds 
structurally related to ThT are also able to increase 
lifespan suggesting that general structural features of 
ThT are important for lifespan extension in C. elegans. 
This result is of particular interest because it implies the 
possibility that other ThT structurally-related 
compounds with different bioavailability and physical 
chemistry properties could be used with similar success 
to increase lifespan or ameliorate conformational 
diseases.  
 
Several models of protein aggregation of the type 
observed in neurodegenerative diseases have been 
developed in C. elegans. Elegant work from the 
laboratories of Richard Morimoto [7] and Christopher 
Link [8], among others, has provided the worm 
community with robust models of protein aggregation 
that we exploited. We tested whether ThT and other 
compounds could also prevent protein aggregation-
associated phenotypes. Indeed, they did. We then used 
another wonderful worm tool, RNA interference, to ask 
whether compound action required endogenous worm 
factors, particulary components of the protein 
homeostasis network. In short, these experiments told 
us that that ThT requires an intact protein homeostasis 
network to produce beneficial effects on these strains. 
In addition, we found that the ThT effect on lifespan 
depends of two transcription factors that have long been 
associated with the control of the stress resistance and 
longevity, Heat Shock Factor 1 (HSF-1) [3] and SKN-1 
[9].  
 
A large body of literature demonstrates that ThT binds 
to amyloid-like aggregating protein [10]. This suggested 
to us that a molecular interaction of the compound with 
misfolded proteins could be occurring in vivo. Although 
we were unable to clearly demonstrate this interaction 
in worms engineered and induced to express amyloid 
for 24 h we were able to visualize ThT in cells 
containing large aggregates. We believe that ThT could 
exert its influence on protein homeostasis initially by 
binding to aberrant forms of protein but may also be 
interacting with protein homeostasis regulatory targets 
or transiently binding to the amyloid itself at early times 
after amyloid induction.   
 
 
These results indicate that the protein homeostatic 
network can be manipulated by using small molecules 
to suppress age-related disease pathologies and 
highlights some important concepts for a novel 
approach to the discovery of new drugs with potential to 
modulate aging and improve the conditions of 
conformational diseases.  
 
We hypothesize that compounds that enable an animal 
to maintain protein homeostasis during aging could be 
active against multiple states of diverse conformational 
diseases. These compounds can be identified by using 
C. elegans models of neurodegenerative disease and 
aging. Perhaps prevention and cures of age-related 
diseases will emerge from chemical screens that target 
aging.   
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